Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Phase 2 N=69 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Phase 2 N=48 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=48 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 2 N=66 A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Phase 2 N=52 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
Phase 2 N=33 Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Squamous Cell Carcinoma of the Head and Neck
Primary: Best Overall Response (BOR) According to Modified World Health Organization (WHO) Criteria — 36.4 percentage of participants
Phase 2 N=95 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Oral Cavity
Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2
Phase 2 N=62 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=33 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Phase 2 N=37 Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants
Phase 2 N=27 Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Head and Neck Cancer
Primary: Overall Response Rate (ORR) — 1; 14; 15; 5 participants
Phase 2 N=14 Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Stage IV Squamous Cell Carcinoma of the Hypopharynx · Stage IV Squamous Cell Carcinoma of the Larynx · Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease) — 2; 9; 2 participants
Phase 3 N=658 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Recurrent and/or Metastatic Head and Neck Cancer
Primary: Overall Survival — 11.1; 9.0 months — p=0.1403
Phase 2 N=54 Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Squamous Cell Head and Neck Carcinoma · Recurrent or Metastatic Disease
Primary: Objective Tumor Response Rate — 44 percentage of participants
Phase 2 N=22 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Phase 1 N=59 Pembrolizumab in Combination With CRT for LA-SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer
Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…
Phase 2 N=48 Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Squamous Cell Cancer · Head and Neck Cancer
Primary: Phase II Recommended Dose for the Combination of Temsirolimus + Weekly Paclitaxel + Carboplatin. — 25 mg
Phase 2 N=172 Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 16.4 Percentage of participants — p=<0.001
Phase 2 N=18 The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants
Phase 2 N=97 Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Head and Neck Cancer
Primary: Progression-Free Survival (PFS) — 1.9; 2.0 months — p=0.0667
Phase 2 N=60 Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04
Phase 2 N=425 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup — 13.2; 18.3 percentage of participants — p=0.2897
Phase 3 N=882 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer
Primary: Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review…
Phase 2 N=40 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Patient Response — 11; 15; 6; 0 participants